2023 World Conference on Lung Cancer (Posters)-EP12.01. Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study

EP12.01. Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study - PDF(Abstract)

Back to course

Pdf Summary

This study compared the efficacy and safety of different combinations of anti-angiogenic agents and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The researchers conducted a retrospective analysis of patients who received first-line EGFR TKI therapy in combination with either bevacizumab or ramucirumab at a medical center in Taiwan between January 2014 and August 2021.<br /><br />Of the 70 patients included in the study, 62 received bevacizumab in combination with EGFR-TKIs and 8 received ramucirumab. The patient characteristics were similar in both groups. The median progression-free survival (PFS) was longer in the bevacizumab group (20.9 months) than in the ramucirumab group (8.7 months), with a hazard ratio (HR) of 0.14. In TKI treatment-naïve patients, bevacizumab exhibited a higher objective response rate and disease control rate, as well as a longer median PFS, compared to ramucirumab.<br /><br />Multivariate analysis showed that female sex, absence of liver metastasis, and administration of bevacizumab were independently associated with a longer PFS. The two groups did not show significant differences in adverse effects, except for more dermatitis acneiform reported in the bevacizumab combinations.<br /><br />The study suggests that in patients with untreated EGFR-mutated metastatic NSCLC, the combination of bevacizumab and EGFR-TKIs may provide better PFS compared to the combination of ramucirumab and EGFR-TKIs. However, larger studies are needed to confirm these findings.<br /><br />This study contributes to the understanding of the real-world clinical applications of different anti-angiogenic agents in combination with EGFR TKIs in the treatment of EGFR-mutated NSCLC. The results support the use of bevacizumab plus EGFR-TKIs as a potential treatment option for these patients.

Asset Subtitle

Ruei-Lin Sun

Meta Tag

Speaker Ruei-Lin Sun

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

efficacy

safety

anti-angiogenic agents

EGFR

tyrosine kinase inhibitors

non-small cell lung cancer

bevacizumab

ramucirumab

progression-free survival

adverse effects